Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 14/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.51 |
| ▸ | HPN | P05981 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5575942 | 1.00 | VCAM1 (0.61) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL14417964 | 1.00 | VCAM1 (0.61) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL6288160 | 0.83 | VCAM1 (0.44) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL5576555 | 0.82 | VCAM1 (0.65) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL5576549 | 0.82 | VCAM1 (0.65) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL14037559 | 0.82 | VCAM1 (0.70) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL5576953 | 0.81 | VCAM1 (0.54) | VCAM1ALOX15HPNMAPTSIRT5 | |
| Elsibucol SCHEMBL6002307 | 0.81 | VCAM1 (0.73) | VCAM1ALOX15HPNMAPTSIRT5 | |
| Camobucol SCHEMBL4734553 | 0.79 | VCAM1 (0.70) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL5576940 | 0.79 | VCAM1 (0.63) | VCAM1ALOX15HPNMAPTSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271274-B2 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | AHTEROGENICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271274-B2 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | AHTEROGENICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271274-B2 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | AHTEROGENICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060020038-A1 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | CRABTREE ACQUISITION CO, LLC | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020038-A1 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | MPO, ALOX15B, ALOX12 | VCAM1 961/4885ALOX15 6/4885HPN 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.